AVDL vs. COLL, BCYC, BDSI, IMUX, AGLE, BBIO, OGN, IONS, CYTK, and APLS
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Collegium Pharmaceutical (COLL), Bicycle Therapeutics (BCYC), BioDelivery Sciences International (BDSI), Immunic (IMUX), Aeglea BioTherapeutics (AGLE), BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector.
Collegium Pharmaceutical (NASDAQ:COLL) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
Collegium Pharmaceutical has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical received 46 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. However, 65.22% of users gave Avadel Pharmaceuticals an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.
69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 4.0% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 4.0% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Collegium Pharmaceutical has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
Collegium Pharmaceutical has a net margin of 16.46% compared to Collegium Pharmaceutical's net margin of -284.42%. Avadel Pharmaceuticals' return on equity of 104.98% beat Collegium Pharmaceutical's return on equity.
Collegium Pharmaceutical currently has a consensus target price of $39.00, suggesting a potential upside of 17.68%. Avadel Pharmaceuticals has a consensus target price of $24.17, suggesting a potential upside of 51.52%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Collegium Pharmaceutical.
In the previous week, Collegium Pharmaceutical had 9 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 13 mentions for Collegium Pharmaceutical and 4 mentions for Avadel Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 0.70 beat Avadel Pharmaceuticals' score of 0.56 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.
Summary
Collegium Pharmaceutical and Avadel Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
